Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 11, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Canadian prostate brachytherapy in 2012.

Mira Keyes1, Juanita Crook, W James Morris

  • 1Prostate Brachytherapy Program, British Columbia Cancer Agency, Vancouver, BC;

Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|May 15, 2013
PubMed
Summary

Prostate brachytherapy, using low dose rate (LDR) or high dose rate (HDR) implants, is an effective radiation treatment for prostate cancer. Canadian programs are summarizing eligibility, outcomes, and toxicity for LDR and HDR brachytherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Participant Heterogeneity in the Prostate Cancer Biobank of the NRG: An Obstacle to Broadening the Reach of Precision Oncology.

JCO precision oncology·2026
Same author

Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer.

Endocrine oncology (Bristol, England)·2026
Same author

Biochemical composition of prostate core-needle biopsies before and after a single fraction of 13.5 Gy: a Raman spectroscopy-based study.

The Analyst·2026
Same author

Core competencies in prostate HDR brachytherapy: An American Brachytherapy Society Endorsed Competency Framework.

Brachytherapy·2026
Same author

Pelvic nodes ultra-hypo fractionated versus conventionally fractionated IMRT with HDR brachytherapy in prostate cancer: interim analysis of a collaborative multi-institutional non-inferiority phase 3 trial (PCS-XI, NCT05820633).

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Global practice patterns in prostate brachytherapy: Results from the ENCOMPASS survey.

Brachytherapy·2026

Area of Science:

  • Oncology
  • Radiation Oncology
  • Medical Physics

Background:

  • Prostate brachytherapy is a key radiation treatment for prostate cancer, used as monotherapy or with external beam radiation therapy (EBRT).
  • Both low dose rate (LDR) and high dose rate (HDR) brachytherapy techniques are established in Canada.
  • The demand for brachytherapy services in Canada is projected to rise significantly.

Purpose of the Study:

  • To review Canadian prostate brachytherapy programs, including eligibility criteria, toxicity, and survival outcomes.
  • To consolidate current data on both LDR and HDR brachytherapy from Canadian institutions.
  • To provide an overview of the current landscape and future needs for prostate brachytherapy in Canada.

Main Methods:

  • Systematic review of published data from Canadian institutions on LDR and HDR prostate brachytherapy.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Experiment Videos

Last Updated: May 11, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

  • Analysis of contemporary eligibility criteria for prostate brachytherapy.
  • Evaluation of toxicity profiles and prostate-specific antigen recurrence-free survival (PRFS) data.

    • Main Results:

    • Prostate brachytherapy is offered across multiple Canadian provinces, with established programs since the 1990s.
    • Data on patient eligibility, treatment toxicity, and PRFS for both LDR and HDR brachytherapy are available from Canadian centers.
    • The review synthesizes findings on efficacy and safety from various Canadian brachytherapy programs.

    Conclusions:

    • Prostate brachytherapy (LDR and HDR) is a well-established and effective treatment modality in Canada.
    • Canadian institutions are actively contributing data on the outcomes and safety of prostate brachytherapy.
    • Anticipated increased demand necessitates continued evaluation and potential expansion of brachytherapy services nationwide.